Artificial Intelligence Enters the World of Medicine!
OpenAI has begun important discussions with officials from the U.S. Food and Drug Administration (FDA) with the aim of using artificial intelligence to accelerate the evaluation process for new drugs 💊
The proposed project is named cderGPT, which is an artificial intelligence system dedicated to supporting the work of the Center for Drug Evaluation within the agency, which is responsible for regulating prescription and over-the-counter drugs in the United States 🧪
Drug development processes typically take more than ten years, particularly in the evaluation and final review stages.
Through this collaboration, OpenAI aims to reduce the time required in this phase, using AI models to analyze data faster and more efficiently.
⚠️ Despite the optimism regarding the potential of AI, there is still a lot of concern, especially regarding the reliability and accuracy of the results provided by AI in precise fields such as health 🧐